On the other hand, in tumors, the loss of ARID1A can lead to low differentiation of cells, upregulated PD-L1 expression, suppression of CD8+ T cell activity, and enhanced tumor malignancy (25, 26). This evidence concerns the gene CD8A and neoplasm.